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Alemtuzumab long-term immunologic
effect
Treg suppressor function increases up to 24 months
ABSTRACT
Objective: To analyze changes in T-helper (Th) subsets, T-regulatory (Treg) cell percentages and
function, and mRNA levels of immunologically relevant molecules during a 24-month follow-up
after alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (RRMS).
Methods: Multicenter follow-up of 29 alemtuzumab-treated patients with RRMS in the Compar-
ison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I and CARE-MS II trials.
Peripheral blood (PB) samples were obtained at months 0, 6, 12, 18, and 24. We evaluated (1)
mRNA levels of 26 immunologic molecules (cytokines, chemokines, chemokine receptors, and
transcriptional factors); (2) Th1, Th17, and Treg cell percentages; and (3) myelin basic protein
(MBP)–specific Treg suppressor activity.
Results: We observed 12 relapses in 9 patients. mRNA levels of the anti-inflammatory cytokines
interleukin (IL)–10, IL-27, and transforming growth factor–b persistently increased whereas
those of proinflammatory molecules related to the Th1 or Th17 subsets persistently decreased
after alemtuzumab administration throughout the follow-up period. PB CD41 cell percentage
remained significantly lower than baseline while that of Th1 and Th17 cells did not significantly
change. A significant increase in Treg cell percentage was observed at month 24 and was accom-
panied by an increase in Treg cell suppressive activity against MBP-specific Th1 and Th17 cells.
Conclusions: The long-lasting therapeutic benefit of alemtuzumab in RRMS may involve a shift in
the cytokine balance towards inhibition of inflammation associated with a reconstitution of the PB
CD41 T-cell subsets that includes expansion of Treg cells with increased suppressive function.
Neurol Neuroimmunol Neuroinflamm 2016;3:e194; doi: 10.1212/NXI.0000000000000194
GLOSSARY
BBB5 blood–brain barrier; CARE-MS5 Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CCL5 C-C motif
ligand; CCR 5 C-C chemokine receptor; CXCL 5 C-X-C motif ligand; CXCR 5 C-X-C chemokine receptor; EDSS 5 Expanded
Disability Status Scale; ELISPOT5 enzyme-linked immunospot; FACS5 fluorescence-activated cell sorting; FoxP35 forkhead
box P3; IFN 5 interferon; IL 5 interleukin; mAb 5 monoclonal antibodies; MBP 5 myelin basic protein; MS 5 multiple sclerosis;
PB 5 peripheral blood; PBMC 5 peripheral blood mononuclear cells; PPD 5 purified protein derivative of tuberculin; RORC 5
retinoid-related orphan receptor g; RR 5 relapsing-remitting; Tbet 5 T-box expressed in T cells; TGF 5 transforming growth
factor; Th 5 T-helper; TNF 5 tumor necrosis factor; Treg 5 T-regulatory cells; VLA 5 very late antigen.
Alemtuzumab is a humanized monoclonal antibody that targets the CD52 antigen, expressed
mainly on the surface of T and B lymphocytes and less on natural killer cells, monocytes,
and dendritic cells.1 Besides its use in fludarabine-resistant B-cell chronic lymphocytic leuke-
mia,2 alemtuzumab was tested in 2 phase III trials (Comparison of Alemtuzumab and Rebif
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Efficacy in Multiple Sclerosis [CARE-MS] I3
and CARE-MS II4) in relapsing-remitting
(RR) multiple sclerosis (MS). These 2 trials
were designed to test the superiority of alem-
tuzumab vs interferon (IFN)–b-1a, 44 mcg
subcutaneously, 3 times a week. Compared
with IFN-b, alemtuzumab significantly
reduced relapse rate by 49%3 to 55%4 and
the risk of sustained accumulation of disability
over 6 months by 42%.4
A single therapeutic course of alemtuzumab
induces severe T- and B-cell depletion, with
lymphocyte repopulation occurring over sev-
eral months,5 and an increase of the percentage
of T-regulatory cells (Treg).
T-helper (Th) subsets are involved in MS
pathology, and brain MS lesions are en-
riched in Th1 and Th17 cells.6 Th17 and
Th1/17 cells (an intermediate subset pro-
ducing interleukin [IL]–17 and IFN-g7)
are increased in the peripheral blood (PB)
and CSF at the time of a new relapse8 and
cross the blood–brain barrier (BBB) more
easily than Th1 cells.9 Some reports have
examined10,11 the CD19, CD4, and CD8
subsets and related cytokine changes in a
few patients treated with alemtuzumab.
No studies have evaluated Treg function in
alemtuzumab-treated patients with MS. We
organized a multicenter 24-month study to
analyze the changes in Th subsets, Treg
proportion and function, and mRNA levels
of cytokines and other immunologically
related molecules during phase III alemtu-
zumab trials.3,4 The long-term follow-up of
immune system reconstitution together
with clinical and radiologic data could pro-
vide practical tools to define the timing of
repeated alemtuzumab courses.
METHODS Patients and clinical study design. Twenty-
nine patients with RRMS12 participating in CARE-MS I3 and
II4 trials in 6 European MS centers entered this study and were
evaluated at baseline and for 24 months after alemtuzumab
treatment. Inclusion and exclusion criteria were described in
the original articles.3,4 Patients were treated with 12 mg/d IV
alemtuzumab in 2 annual courses (5 administrations at month
0 and 3 administrations at month 12). Patients’ demographic and
clinical characteristics are reported in the table. Neurologic
assessments, performed by blinded investigators, were done at
baseline and repeated every month or in case of relapses. Blood
samples were taken at baseline (before first alemtuzumab course)
and at months 6, 12 (before second alemtuzumab course), 18,
and 24. At each time point, blood cell count, coagulation,
thyroid, liver, and kidney function were analyzed in a central
facility. Fresh blood was collected in heparin-treated vacutainers
and immediately sent to a single coordinating center located at
the University of Torino for immunologic testing. All samples
were received and processed within 48 hours from the blood
withdrawal.
Standard protocol approvals, registrations, and patient
consents. The institutional review board of the participating
centers approved the study and all subjects gave written informed
consent (protocol number Bio2009001).
Cytokine mRNA analysis. Aliquots (0.5 mL each) of blood
were mixed with 1.3 mL RNAlater (Ambion, Life Technologies,
Carlsbad, CA) immediately after arrival at the coordinating center
and stored at 280°C. To determine mRNA levels, samples were
treated as previously described13: RNA was extracted with the
RiboPure Blood Kit (Ambion) and cDNA obtained with the
high-capacity cDNA reverse transcription kit (Applied
Biosystems, Life Technologies, Monza, Italy).13
We assessed the mRNA levels of the following 26 immuno-
logically relevant molecules whose function in MS has been docu-
mented by using TaqMan low-density arrays (Applied Biosystems
7900HT real-time PCR system)13: molecules with proinflamma-
tory function including IL-1b,14 IL-2,15 IL-6,16 IL-12,17
IL-17A,18 IL-17F,19 IL-21,20 IL-22,21 IL-23,22 IL-26,23 IFN-g,14
T-box expressed in T cells (Tbet),23 retinoid-related orphan
receptor g (RORC),24 tumor necrosis factor–a (TNF-a),25
C-C chemokine receptor type 3 (CCR3),26 CCR4,27 CCR5,26
CCR6,28 C-X-C chemokine receptor type 3 (CXCR3),29
C-X-C motif ligand 10 (CXCL10),29 C-C motif ligand 20
(CCL20),30 and very late antigen 4 (VLA4)31; and molecules with
anti-inflammatory function, including IL-10,32 IL-27,33 trans-
forming growth factor–b (TGF-b),32 and forkhead box P3
(FoxP3).34 Glyceraldehyde-3 phosphate dehydrogenase served
as the housekeeping gene for normalization. The relative expres-
sion of each gene was calculated using the comparative threshold
cycle method as directed by the manufacturer (User Bulletin
No. 2, Applied Biosystems) and expressed in arbitrary units as
previously described in detail.13
Flow cytometry (fluorescence-activated cell sorting
[FACS]). PB mononuclear cells (PBMC) were isolated by den-
sity gradient centrifugation from heparinized venous blood.
PBMC were stained for Treg cells with anti-CD4, anti-CD25,
and anti-CD127 monoclonal antibodies (mAb) (Biolegend, San
Diego, CA) on the cell surface. For detection of the
transcriptional factor FoxP3, cells were fixed with fixation and
permeabilization buffers (eBioscience, San Diego, CA) and
were then stained with anti-FoxP3 mAb (eBioscience). The
Table Demographic data
Values
Sex, F/M 17/12
Age at baseline, y 34 6 8.7
Age at onset, y 28.2 6 9.2
EDSS at baseline 2.5 6 1.1
Disease duration, y 5 6 3.5
No. relapses in the 2 y before baseline 1.7 6 1.1
Abbreviation: EDSS 5 Expanded Disability Status Scale.
Values are n or mean 6 SD.
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expression of IL-17 and IFN-g was analyzed by intracellular
cytokine staining.8,20 PBMC were cultured in Iscove’s modified
Dulbecco’s medium (BioWhittaker, Walkersville, MD)
supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA) and stimulated for 5 hours with Phorbol
12-myristate 13-acetate PMA (50 ng/mL) and ionomycin (500
ng/mL) in the presence of brefeldin A (10mg/mL, Sigma-Aldrich,
St. Louis, MO). Cells were first stained for the surface antigen
CD4 (Biolegend) and then fixed with 4% paraformaldehyde,
permeabilized with 0.5% saponin, followed by intracellular
staining with anti-IL-17 and anti-IFN-g mAbs (Biolegend).
Stained PBMC were acquired on a FACSCalibur (BD
Biosciences, San Jose, CA) and analyzed with FlowJo software
(Ashland, OR).
Enzyme-linked immunospot (ELISPOT) assay. Antigen-
specific IFN-g and IL-17-producing cells and antigen-specific
suppressor activity of Treg cells were assessed by ELISPOT
(eBioscience) at months 0, 12, and 24. To remove Treg cells
from PBMC (PBMCCD252), the CD251 fraction was depleted
using immunomagnetic beads (Miltenyi Biotec, Bergisch
Gladbach, Germany). 1 3 105 Total PBMC or PBMCCD252
were seeded in 96-well ELISPOT assay plates (Millipore,
Darmstadt, Germany) in triplicate and incubated for 48 hours
at 37°C either with myelin basic protein (MBP, 40 mg/mL,
Sigma-Aldrich) or with purified protein derivative of
tuberculin (PPD, 40 mg/mL, Sigma-Aldrich) as control.8
IFN-g-specific or IL-17-specific spots were counted by
computer-assisted image analysis (Transtec 1300 ELISpot
Reader; AMI Bioline, Buttigliera Alta, Italy). The number of
IFN-g or IL-17 spots produced spontaneously was subtracted
from the number of spots produced by antigen-stimulated cells
to obtain the number of IFN-g and IL-17 antigen-specific
spots in the PBMC or in the PBMCCD252, as previously
described.8
Statistical analysis. Statistical analysis was performed using
Prism 5.0 GraphPad (La Jolla, CA) software. For the longitudinal
follow-up, statistical significance was calculated with respect
to baseline by using one-way analysis of variance for repeated
measures followed by Bonferroni multiple comparison
posttest.8,20 Pearson t test was used to analyze the differences
between groups. p Values #0.05 were considered statistically
significant.
RESULTS Clinical results. A cohort of 29 patients with
RRMS was followed for 24 months during the CARE-
MS I3 and II4 trials. Three patients did not receive the
second alemtuzumab course, 2 owing to early study
dropout and another owing to the occurrence of
thrombocytopenia. The most common adverse events
were cutaneous rashes. Thrombocytopenia and isolated
neutropenia occurred in 2 patients, respectively, 4 and
6 months after the first course. A few infections
occurred: herpes labialis (2 cases), mild upper
respiratory tract (7 cases) and lower urinary tract
(6 cases) infections, and one case of pneumonia.
A single case of autoantibody-negative subclinical
hypothyroidism was registered. No patient developed
a serious adverse event.
Nine patients experienced a total of 12 clinical re-
lapses (figure e-1 on the Neurology® Web site at
Neurology.org/nn). The mean Expanded Disability
Status Scale (EDSS) score did not change significantly
during the 24-month follow-up (EDSS score from 2.
5 at baseline to 2.3 at month 24).
Increase in anti-inflammatory cytokines and decrease in
proinflammatory cytokines, chemokines, and chemokine
receptors. PB mRNA levels of the anti-inflammatory
cytokines IL-10, IL-27, and TGF-b significantly
increased at each time point after alemtuzumab
treatment compared with baseline. FoxP3 mRNA
significantly increased at month 12 and thereafter
(figure 1A). mRNA levels of proinflammatory
cytokines and transcriptional factors related to the
Th17 (IL-1B, IL-6, IL-17A, IL-17F, IL-23, IL-26,
TNF-a, RORC) and Th1 subset (IL-12, IFN-g,
Tbet), and of proinflammatory chemokines or
chemokine receptors (CCR3, CCR4, CCR5,
CCR6, CXCR3, CXCL10, CCL20, VLA4) (figure
1B), significantly decreased at each time point
compared with baseline, except for IL-22, which
did not decrease at month 18. Overall, the observed
increases and decreases in mRNA levels occurred
during the first 12 months, and remained at values
similar to month 12 thereafter. Interestingly, IL-2, a
cytokine that promotes T-cell proliferation,
significantly increased at month 18 and 24 (figure
1B). We did not observe any differences in any of
the mRNA levels either before or after treatment in the
3 patients who developed autoimmune adverse events
compared to the other patients. Unlike what was
observed in another group of alemtuzumab-treated
patients,35 IL-21 decreased after alemtuzumab
treatment in all our patients, regardless of the
occurrence of autoimmune adverse events. This
difference might be related to the difference in the
technique used to determine IL-21, i.e., the
detection of the protein mRNA in our study or
the protein itself with ELISA in the other reports.35
Increase in Treg cells percentage and function in the late
phase of alemtuzumab treatment follow-up. CD41 cell
percentage in the PBMC rapidly decreased after the
first course. At month 6, it was reduced by 66% com-
pared to baseline and, although the percentage
increased in the following months, it still remained
significantly lower than baseline throughout the
follow-up (figure 2A). We did not observe any
significant changes in the percentage of Th1 or
Th17 (single producing or IL-17 and IFN-g
coproducing) cells within the CD41 fraction at any
of the time points (figure 2B); however, the absolute
numbers of Th17 and Th1 cells were significantly
decreased after alemtuzumab administration (figure
e-2). Of interest, a significant increase from
baseline of IL-17 CD41-producing cells,
accompanied by IL-2 mRNA increase in the
blood, was observed in 6 patients who had a
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clinical relapse aroundmonth 18 (figure 3). A significant
increase in CD41CD25highCD127lowFoxP31 Treg cell
percentage was observed at month 24 (figure 2C).
To understand if the increase was due to an
expansion of the memory Treg cell compartment
or to a de novo production of naive Treg cells,
we analyzed the expression of CD45RA and
CD45RO in the FoxP31 fraction. We observed
Figure 1 mRNA levels in peripheral blood mononuclear cells of patients with multiple sclerosis treated with alemtuzumab
mRNA levels of anti-inflammatory (A) and proinflammatory (B) molecules are presented as arbitrary units (AU) (see Methods) at months 0, 6, 12, 18, and 24.
Horizontal black lines indicatemeans. Statistical significance (one-way analysis of variance) is calculated with respect to baseline (month 0) values, and indicated
as *p , 0.05, **p , 0.001, ***p , 0.0001. CCL 5 C-C motif ligand; CCR 5 C-C chemokine receptor; CXCL 5 C-X-C motif ligand; CXCR 5 C-X-C chemokine
receptor; FoxP35 forkhead box P3; IFN5 interferon; IL5 interleukin; TGF5 transforming growth factor; TNF5 tumor necrosis factor; VLA5 very late antigen.
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a significant increase in the percentage of
memory CD45RO1CD41FoxP31 lymphocytes,
accompanied by a relative contraction of the
percentage of naive CD45RA1CD41FoxP31
lymphocytes.
Suppressor function was assessed by measuring the
antigen-specific IFN-g and IL-17 production in the
PBMC before and after CD251 fraction depletion. If
the CD251 T-cell fraction contained cells with
regulatory activity, an increase in IFN-g and IL-17
production by PBMCCD252 cells should occur after
depletion. At baseline, 33% of the patients displayed
an increase in MBP-specific spots after Treg deple-
tion. This percentage increased slightly to 42% at
month 12, and further increased to 60% (signifi-
cantly compared to baseline) at month 24 (figure
4). This increase in suppressor function was specific
for MBP, a CNS antigen, and did not occur for PPD
(data not shown).
DISCUSSION Our study suggests that alemtuzumab
long-lasting therapeutic effect in MS may involve a
shift in the cytokine balance towards inhibition of
inflammation associated with a reconstitution of the
PB CD41 T-cell subsets involving the expansion of
Treg cells with increased suppressive function.
In agreement with previous studies,5,11 we
observed a dramatic and early reduction of the
CD41 population in our patients. The reconstitu-
tion of CD41 lymphocytes occurred slowly and 24
Figure 2 CD41 T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear
cells of patients with multiple sclerosis treated with alemtuzumab
(A) CD41 lymphocyte percentage. (B) Interleukin (IL)–17, interferon (IFN)–g, and IL-17/IFN-g-producing cell percentage
among the CD41 fraction. (C) CD41CD25highCD127lowforkhead box P3 (FoxP31) T-regulatory cells lymphocyte percent-
age among the CD41 fraction. (D) Percentage of CD41FoxP31 cells expressing CD45RO and CD45RA. Statistical sig-
nificance (one-way analysis of variance) is calculated with respect to baseline (month 0) values, and indicated as *p, 0.05,
**p , 0.001, ***p , 0.0001.
Figure 3 T-helper 17 cells and interleukin (IL)–2
mRNA were higher in patients who
relapsed
Fluorescence-activated cell sorting analysis of IL-17-producing
cell percentage among the CD41 fraction (A) and mRNA
levels of IL-2 (B) at months 0 and 18 in 6 patients with a
documented relapse around month 18. **p , 0.001, ***p ,
0.0001, Pearson t test. AU 5 arbitrary units.
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months after the first alemtuzumab administration
the percentage of CD41 cells was still approximately
half of the baseline level.
Th1 and Th17 cells are important effectors in the
pathogenesis of RRMS,6,8,20,36,37 whereas Treg cells
counteract their encephalitogenic effect.38 The num-
ber of Th17 and Th1 cells in the blood and the
mRNA transcripts of proinflammatory cytokines
and transcription factors related to these subsets
decreased at all timepoints after alemtuzumab admin-
istration compared to baseline. Analysis of the mRNA
levels revealed profound modification after treatment
as a significant decrease of chemokine receptors
related to Th17 (CCR6,28 CCR427) and Th1 cells
(CCR3,26 CCR5,26 CXCR329) infiltration into the
CNS, and of the VLA-4 integrin, which plays a role
in T-cell penetration of the BBB, was observed. Two
chemokines that are thought to play a role in the
pathogenesis of MS, CCL20 and CXCL10, were sig-
nificantly decreased after treatment as well. CCL20 is
secreted both by the epithelial cells of the inflamed
BBB that recruits CCR61 Th17 cells as well as by
Th17 themselves and its serum level was found sig-
nificantly increased in patients with RRMS.30
CXCL10 serum/tissue ratio is increased in MS.29
These data suggest that the beneficial effects of
alemtuzumab in MS are due to a reduction of both
proinflammatory cytokines and T-cell recruitment
into the CNS.
IL-27, TGF-b, and IL-10 mRNA levels increased
after 6 and 12 months and exceeded baseline levels up
to 24 months after treatment. The dendritic cell-
derived IL-27 cytokine is an important inhibitor of
Th17/Th1 responses.39 TGF-b and IL-10 increase
Treg cell functions; in MS, IL-10 production is
decreased prior to relapses and increased during
clinical remission. Increase in the mRNA levels of
these cytokines suggests that alemtuzumab shifts the
balance towards the production of anti-inflammatory
cytokines. The mRNA level of FoxP3 was also upre-
gulated in the blood starting from 12 months after
alemtuzumab treatment and even increasing after 24
months, suggesting a Treg cell expansion in number
and function. Our study has identified a significantly
long-lasting posttreatment increase in Treg cell
percentage and function, differently from other
reports,5,11 where the percentage of Treg cells
slowly returns to baseline over 12 months post-
alemtuzumab. At month 24, a significant increase
in the CD41CD25highCD127lowFoxP31 Treg cell
percentage in the PBMC was observed. Moreover,
we measured a significant increase in MBP-specific
suppressive function, suggesting that the expanded
Treg cells specifically suppress myelin-induced autoim-
mune responses. In agreement with Havari et al.,40 we
observed that after alemtuzumab, the percentage of
Treg increased, along with an increase of suppressive
activity mediated by contact-dependent and contact-
independent mechanisms such as IL-2 consumption.
IL-2 is required for effector T-cell proliferation and for
Treg function and proliferation. However, further
studies are needed to understand the meaning of the
increase in Treg cell-suppressive function in the late
phase of alemtuzumab treatment follow-up.
From this clinical and immunologic study during
a 24-month follow-up after alemtuzumab treatment,
we can draw the conclusion that alemtuzumab
clinical efficacy may be related to its long-term effects
on the immune system, bringing about a significant
and long-lasting reduction in the production of
proinflammatory molecules and an increase in anti-
inflammatory activity.
In particular, an increase of molecules related to
Treg cells was found.
This goes along with the finding of increased Treg
suppressor function, which peaked 24 months after
alemtuzumab administration, probably indicating a
favorable immunoreconstitution. The continuation
of this study up to 48 months of follow-up after the
first alemtuzumab administration may provide useful
clinical information, for example about the possible
timing for further courses of this treatment.
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